Kilitch Drugs (India) Share Price

NSE
KILITCH •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Kilitch Drugs (India) Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
Near 52W Low of ₹300.00
-5.6
TTM PE Ratio
Below industry Median
25.6
Price to Book Ratio
Below industry Median
2.6
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.8

Kilitch Drugs (India) Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Kilitch Drugs (India) Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
56.17 Cr
47.47 Cr
33.45 Cr
44.82 Cr
31.79 Cr

Kilitch Drugs (India) Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
158.85 Cr
142.52 Cr
117.14 Cr
71.19 Cr
57.45 Cr

Kilitch Drugs (India) Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
5.61 Cr
8.61 Cr
0.11 Cr
3.68 Cr
1.74 Cr

Kilitch Drugs (India) Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
13.58 Cr
8.28 Cr
6.21 Cr
3.77 Cr
0.84 Cr
Kilitch Drugs (India) Result Highlights
  • Kilitch Drugs (India) Ltd reported a 10.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 66.6%.

  • Its expenses for the quarter were up by 17.4% QoQ and 55.5% YoY.

  • The net profit decreased 34.8% QoQ and increased 222.4% YoY.

  • The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 3.7 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Kilitch Drugs (India) shareholding Pattern

Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%

Kilitch Drugs (India) Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
319.80
10Day EMA
320.10
12Day EMA
320.40
20Day EMA
322.00
26Day EMA
323.00
50Day EMA
324.90
100Day EMA
328.30
200Day EMA
329.70
5Day SMA
321.40
10Day SMA
318.80
20Day SMA
322.60
30Day SMA
327.70
50Day SMA
327.10
100Day SMA
325.60
150Day SMA
333.90
200Day SMA
334.70
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
15603 Rs
24727 Rs
Week Rs
12873 Rs
16598 Rs
Month Rs
5826 Rs
8278 Rs
Resistance & Support
317.70
Pivot
Resistance
First Resistance
329.85
Second Resistance
342.15
Third Resistance
354.30
Support
First Support
305.40
Second support
293.25
Third Support
280.95
Relative Strength Index
45
Money Flow Index
22.19
MACD
-2.56
MACD Signal
-2.79
Average True Range
15.59
Average Directional Index
20.81
Rate of Change (21)
-4.77
Rate of Change (125)
-4.60

Kilitch Drugs (India) Company background

Founded in: 1992
Managing director: Mukund P Mehta
Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables Ophthalmic, Effervescent tablets Granules, Tablets Capsules, OTC range covering varied Nutraceuticals Cosmetics and Medical devices.The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.
Read More

Kilitch Drugs (India) FAQs

Kilitch Drugs (India) Ltd share price is ₹310.65 in NSE and ₹306.05 in BSE as on 13/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Kilitch Drugs (India) Ltd share price in the past 1-year return was -22.14. The Kilitch Drugs (India) Ltd share hit a 1-year low of Rs. 300 and a 1-year high of Rs. 430.

The market cap of Kilitch Drugs (India) Ltd is Rs. 510.69 Cr. as of 13/2/2025 12:00:00 AM.

The PE ratios of Kilitch Drugs (India) Ltd is 21.64 as of 13/2/2025 12:00:00 AM.

The PB ratios of Kilitch Drugs (India) Ltd is 2.14 as of 13/2/2025 12:00:00 AM

You can easily buy Kilitch Drugs (India) Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -